RYTM Q3 2024 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+47.8% YoY

Gross Profit

$29M88.5% margin

Operating Income

-$44M-132.0% margin

Net Income

-$44M-131.2% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

+14.4%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$364M

Total Liabilities

$211M

Stockholders' Equity

$153M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$23M	+47.8%
Gross Profit	$29M	$20M	+46.4%
Operating Income	-$44M	-$44M	+0.2%
Net Income	-$44M	-$44M	+1.2%

Geographic Segments

UNITED STATES

$23M70%

Other Countries

$6M19%

GERMANY

$4M11%